文献速递免疫规划传染病防控与疫情报告

COVID-19 mRNA疫苗接种在既往SARS-CoV-2感染成人中预防COVID-19相关住院的效果——美国,2021年6月至2022年2月

Effectiveness of COVID-19 mRNA Vaccination in Preventing COVID-19-Associated Hospitalization Among Adults with Previous SARS-CoV-2 Infection - United States, June 2021-February 2022.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2022-04-15

采用检测阴性设计,基于Cosmos电子健康记录数据集,比较3,761例病例患者与7,522例匹配对照患者的疫苗接种状态。既往SARS-CoV-2感染成人中,Delta优势期接种2剂疫苗的估计疫苗有效性为47.5%,加强剂为57.8%;Omicron优势期分别为34.6%和67.6%。所有符合条件者包括既往感染者应保持最新疫苗接种以预防COVID-19相关住院。

要点

  • 既往SARS-CoV-2感染成人接种2剂mRNA疫苗对COVID-19相关住院的估计VE在Delta优势期为47.5%,Omicron优势期为34.6%。
  • 加强剂接种后估计VE在Delta优势期为57.8%,Omicron优势期为67.6%,保护水平最高。
  • 所有符合条件者包括既往SARS-CoV-2感染者应保持最新疫苗接种以预防COVID-19相关住院。

核心结论

  • 疫苗接种为既往SARS-CoV-2感染的成人提供针对COVID-19相关住院的保护,加强剂接种提供的保护水平最高。
  • 所有符合条件者包括既往SARS-CoV-2感染者应保持最新疫苗接种以预防COVID-19相关住院。

研究设计与样本

  • 采用检测阴性设计,估计COVID-19 mRNA疫苗在既往核酸扩增检测(NAAT)阳性或COVID-19诊断的≥18岁成人中预防后续COVID-19相关住院的有效性。
  • 分析使用Cosmos电子健康记录(EHR)聚合数据集,比较3,761例病例患者(与住院相关的NAAT阳性结果)与7,522例匹配对照患者(NAAT阴性结果)的疫苗接种状态。

主要发现

  • 既往SARS-CoV-2感染后,Delta优势期(2021年6月20日至12月18日)接种2剂疫苗的估计疫苗有效性(VE)为47.5%(95%CI=38.8%-54.9%),加强剂接种后为57.8%(95%CI=32.1%-73.8%)。
  • Omicron优势期(2021年12月19日至2022年2月24日)接种2剂疫苗的估计VE为34.6%(95%CI=25.5%-42.5%),加强剂接种后为67.6%(95%CI=61.4%-72.8%)。

关键数值与推荐

  • 既往SARS-CoV-2感染后,Delta优势期2剂疫苗估计VE为47.5%(95%CI=38.8%-54.9%),加强剂为57.8%(95%CI=32.1%-73.8%)。
  • Omicron优势期2剂疫苗估计VE为34.6%(95%CI=25.5%-42.5%),加强剂为67.6%(95%CI=61.4%-72.8%)。

临床怎么用

  • 所有符合条件者包括既往SARS-CoV-2感染者应保持最新疫苗接种以预防COVID-19相关住院。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Previous infection with SARS-CoV-2, the virus that causes COVID-19, has been estimated to confer up to 90% protection against reinfection, although this protection was lower against the Omicron variant compared with that against other SARS-CoV-2 variants (1-3). A test-negative design was used to estimate effectiveness of COVID-19 mRNA vaccines in preventing subsequent COVID-19-associated hospitalization among adults aged ≥18 years with a previous positive nucleic acid amplification test (NAAT) or diagnosis of COVID-19.† The analysis used data from Cosmos, an electronic health record (EHR)-aggregated data set (4), and compared vaccination status of 3,761 case-patients (positive NAAT result associated with hospitalization) with 7,522 matched control-patients (negative NAAT result). After previous SARS-CoV-2 infection, estimated vaccine effectiveness (VE) against COVID-19-associated hospitalization was 47.5% (95% CI = 38.8%-54.9%) after 2 vaccine doses and 57.8% (95% CI = 32.1%-73.8%) after a booster dose during the Delta-predominant period (June 20-December 18, 2021), and 34.6% (95% CI = 25.5%-42.5%) after 2 doses and 67.6% (95% CI = 61.4%-72.8%) after a booster dose during the Omicron-predominant period (December 19, 2021-February 24, 2022). Vaccination provides protection against COVID-19-associated hospitalization among adults with previous SARS-CoV-2 infection, with the highest level of protection conferred by a booster dose. All eligible persons, including those with previous SARS-CoV-2 infection, should stay up to date with vaccination to prevent COVID-19-associated hospitalization.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Plumb ID, Feldstein LR, Barkley E, et al. Effectiveness of COVID-19 mRNA Vaccination in Preventing COVID-19-Associated Hospitalization Among Adults with Previous SARS-CoV-2 Infection - United States, June 2021-February 2022. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35421077. doi:10.15585/mmwr.mm7115e2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。